Cardiac fibroblasts (CF) express adenosine (ADO) receptors, and pharmacological evidence suggests the possible involvement of the A2 (A2a and A2b) receptor (A2aR and A2bR) subtypes in inhibiting cell functions involved in fibrosis. The main objective of this study was to define the contributions of A2a and/or A2b receptors in modulating ADO-induced decreases in CF functions. For this purpose, CF were either treated pharmacologically or had the A2aR or A2bR levels modified through the use of recombinant adenovirus or siRNA. The assessment of mRNA expression in adult rat CF yielded evidence for A 1R, A2bR, A2aR, and A3R. Endogenously or exogenously enhanced ADO significantly inhibits CF proliferation, collagen, and protein synthesis. A 2R and A2aR agonists, although capable of inhibiting CF protein and collagen synthesis, were unable to define the contributions derived from A 2aR or A2bR. Overexpression of A 2bR in CF yielded significant decreases in basal levels of collagen and protein synthesis and correlated with increases in cAMP levels. However, at higher doses of ADO receptor agonists, significant increases in protein and collagen synthesis were observed. CF with underexpression of A 2bR yielded increases in protein and collagen synthesis. In contrast, A 2aR underexpression did not modify ADOinduced decreases in CF protein or collagen synthesis. In conclusion, results derived from the molecular manipulation of receptor levels indicate that A 2bR are critically involved in ADO-mediated inhibition of CF functions. collagen deposition; extracellular matrix; remodeling THE INCREASED INCIDENCE of congestive heart failure has stimulated therapeutic efforts to develop pharmacological strategies to prevent or treat the adverse processes of cardiac remodeling. Current therapies are mainly focused on blocking the actions of neurohormonal factors known to stimulate cardiac remodeling. However, the possibility of exploiting endogenously generated factors that are capable of inhibiting this process is only beginning to be assessed (25). An important component of the remodeling process observed with heart failure is the excess deposition of extracellular matrix (ECM) proteins (3). The main cell type responsible for the production of myocardial ECM proteins is the cardiac fibroblast (CF). Thus strategies intended to diminish the production of ECM proteins in the heart may specifically target surface receptors expressed by these cells.
For this purpose, CF were either treated pharmacologically or had the A2aR or A2bR levels modified through the use of recombinant adenovirus or siRNA. The assessment of mRNA expression in adult rat CF yielded evidence for A 1R, A2bR, A2aR, and A3R. Endogenously or exogenously enhanced ADO significantly inhibits CF proliferation, collagen, and protein synthesis. A 2R and A2aR agonists, although capable of inhibiting CF protein and collagen synthesis, were unable to define the contributions derived from A 2aR or A2bR. Overexpression of A 2bR in CF yielded significant decreases in basal levels of collagen and protein synthesis and correlated with increases in cAMP levels. However, at higher doses of ADO receptor agonists, significant increases in protein and collagen synthesis were observed. CF with underexpression of A 2bR yielded increases in protein and collagen synthesis. In contrast, A 2aR underexpression did not modify ADOinduced decreases in CF protein or collagen synthesis. In conclusion, results derived from the molecular manipulation of receptor levels indicate that A 2bR are critically involved in ADO-mediated inhibition of CF functions. collagen deposition; extracellular matrix; remodeling THE INCREASED INCIDENCE of congestive heart failure has stimulated therapeutic efforts to develop pharmacological strategies to prevent or treat the adverse processes of cardiac remodeling. Current therapies are mainly focused on blocking the actions of neurohormonal factors known to stimulate cardiac remodeling. However, the possibility of exploiting endogenously generated factors that are capable of inhibiting this process is only beginning to be assessed (25) . An important component of the remodeling process observed with heart failure is the excess deposition of extracellular matrix (ECM) proteins (3) . The main cell type responsible for the production of myocardial ECM proteins is the cardiac fibroblast (CF). Thus strategies intended to diminish the production of ECM proteins in the heart may specifically target surface receptors expressed by these cells.
The nucleoside adenosine (ADO) has been described as a retaliatory autocoid possessing homeostatic activities in the regulation of myocardial blood flow, catecholamine stimulation, and reduction of ischemic injury (30) . Many of the effects that ADO exerts, such as the ability to suppress proinflammatory cytokine production and release, are consistent with the concept that ADO may inhibit the process of cardiac remodeling (22) . There is indirect evidence that supports the hypothesis that enhanced endogenous ADO levels may attenuate the process of ventricular remodeling in heart failure. Loh et al. (24) observed that congestive heart failure patients that inherited a mutant AMP deaminase gene-1 experienced a significantly greater probability of survival without cardiac transplantation. The authors speculated that inheritance of this mutant allele might be advantageous to patients with congestive heart failure in that the reduction of AMP deaminage gene-1 activity leads to enhanced production of ADO in tissues. There is also evidence that enhanced ADO levels achieved by inhibition of cellular reuptake mechanisms may exert anti-fibrotic effects in models of postsurgery tissue adhesion (28) .
Four main types of ADO receptors are known to exist: A 1 R, A 2a R, A 2b R, and A 3 R (23, 32) . Fibroblasts are known to express these receptors, including the low-affinity A 2b R (5). However, the expression profile of ADO receptors in CF has not been determined. ADO has recently been reported to be able to inhibit various CF functions. Data derived from the use of various selective and nonselective ADO receptor agonists and antagonists indicated that the effects were potentially mediated via A 2b R (6, 9, 10) . However, despite recent advances in the development of new agonists and antagonists, the use of pharmacological agents still poses significant limitations in our ability to discriminate which type of ADO receptors are involved. This is particularly true given the disparity in affinity for ADO agents that exists between two closely related G s coupled receptor subtypes (A 2a and A 2b ) and the fact that both of them appear to signal through common intracellular pathways (i.e., cAMP). Accordingly, in this study, we utilize molecular approaches to over-or underexpress A 2a R or A 2b R to ascertain for ADO receptor subtype involvement in the modulation of CF functions.
MATERIALS AND METHODS
CF isolation and culture. Primary adult rat CF cultures were generated from ventricular tissues of 6-to 8-wk-old male SpragueDawley rats (250 -275 g), as previously described (33) . Briefly, the rats were euthanized and the hearts were removed. The rats were treated according to the principles of the NIH "Guide for the Care and Use of Laboratory Animals" protocols.
Ventricular tissue was isolated, minced, and digested with the use of a solution containing collagenase (100 U/ml) and pancreatin (0.6 mg/ml). Isolated CF were seeded into 10-cm dishes containing growth media DMEM (GIBCO BRL), 10% FBS, and 1% penicillin-streptomycin-fungizone in a humidified atmosphere of 7% CO 2. All studies were performed with cells at passage 2, and characterized as previously published (33) .
CF treatment. CFs were initially grown to the desired confluency in growth media and rendered quiescent by serum starving for 24 h. For experiments involving the over-or underexpression of A 2bR, 70% confluent CFs were exposed to recombinant A2bR adenovirus or small-interference RNAs (siRNAs). CF starvation was performed until adenovirus-infected or siRNA-transfected CF reached 100% confluency. Before treatment culture, the media were replaced with DMEM ϩ 2.5% FBS. To test the effects of increasing endogenous or exogenous levels of ADO we used an adenosine kinase inhibitor (AKI), iodotubercidin (Itu), or an ADO analog, 2-chloroadenosine (Cl-Ad), respectively. Itu at the doses used has previously been shown to increase ADO levels in cultured CF (8) . Micromolar 5Ј-(N-ethylcarboxamido) adenosine (NECA) was used as an ADO A 2R agonist. The agonists 4-[N-ethy-(5Ј-carbamoyladenos-2yl)-aminoethyl]-phenylpropinoic acid (CGS-21680) or 4-{3-[6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2ynyl}-cyclohexylmethyl ester (ATL-193) were used to selectively stimulate A 2aR. All cell culture experiments were performed at least three times each in triplicate.
Construction of recombinant A 2bR adenoviruses. Human A2bR (HA2bR) cDNA was a gift from Dr. D. Marquardt (University of California, San Diego). To construct the HA2bR-expressing adenovirus shuttle vector, the HA2bR cDNA was subcloned into the pACCMV. PLPASR(Ϫ) vector with the use of established methods (18) . The resulting plasmid was confirmed with the use of restriction enzyme digestion and DNA sequencing. The HA 2bR-expressing plasmid was then cotransfected into 293 cells with PJM17 using PolyFect transfection reagent (Qiagen; Valencia, CA). Plaques were isolated, propagated in 293 cells, and purified. The contamination of wild-type virus was ruled out by RT-PCR (35) . Viral titers of purified stocks were then determined. To monitor transfection efficiency, green fluorescent protein (GFP)-expressing HA 2bR recombinant adenoviruses were made according to an established protocol (19) . A multiplicity of infection (MOI) of 200:1 yielded an 80% infection rate in CF without cytotoxicity (Fig. 1A) . The HA 2bR adenovirus was validated by RT-PCR and Western blot analysis (Fig. 1B) . A control adenovirus was generated by recombination of reverse-oriented HA 2bR cloned into the shuttle vector with PJM17. As assessed through RT-PCR, the overexpression of HA 2bR in CF did not yield evidence of alterations in native rat A2aR or A2bR expression levels (data not shown).
Preparation and transfection of siRNA. Three pairs of rat A2aR or A2bR siRNA oligonucleotide templates were designed uniquely against rat A2aR or A2bR. The siRNA sequences targeting rat A2aR corresponded to the coding regions from 795, 1566, and 1913, and rat A 2bR corresponded to the coding regions from 233, 539, and 718 plus the next 19 nucleotides as potential siRNAs. Sequences were blasted against genome databases to eliminate any sequences with homology to other genes. Selected target mRNA sequences for A 2aR are the following: siRNA 795: 5Ј-AATTATCATGGTTTACTACAAC-3Ј; siRNA 1566: 5Ј-AAGGGAAGAGAAACCCAATGG-3Ј; and siRNA 1913: 5Ј-AAGTGGCACTTGGCTATTTCT-3Ј. The selected target mRNA sequences for A 2bR are the following: siRNA 233: 5Ј-AAC-UACUUUCUGGUGUCCCUG-3Ј; siRNA539: 5Ј-AACAGUAAA-GACCGUGCCACC-3Ј; siRNA718: 5Ј-AAUCUUCAUGGUGGC-CUGCAA-3Ј; and control siRNA: 5Ј-AACGGCGACUACUAU-GUGCUU-3Ј.
siRNA duplexes were synthesized with the use of a Silencer siRNA construction kit (Ambion; Austin, TX) and labeled with Cy3 to monitor transfection efficiency. The silencing capacity of the siRNAs was verified by RT-PCR and Western blot analysis. Of the three siRNAs designed, siRNA 1913 and siRNA539 were the most effective in silencing A 2aR and A2bR, respectively, in CF (Fig. 2B ). For siRNA transfection into CF, cells were grown in a 12-well plate to 70% confluency. CFs were divided into three groups for each A 2aR or A2bR siRNA: transfection reagent only, transfected with control siRNA, A2aR siRNA1913, or A2bR siRNA539. siRNAs were introduced into CF by GenePORTER transfection reagent (Gene Therapy System; San Diego, CA). A final concentration of 0.17 mol/l siRNA yielded 70% transfection efficiency with minimum cytotoxicity (Fig. 2A) .
RT-PCR. Total RNA was extracted with the use of a RNeasy Kit (Qiagen), followed by DNase digestion. One microgram of total RNA was then reverse transcribed into cDNA using RT-PCR Kit (Invitrogen; Carlsbad, CA). Four microliters of cDNA were used for PCR. PCR was performed with an initial step of denaturation at 94°C 3 min, 35 cycles of 30 s at 94°C, 30 s at 56°C, and 30 s or 60 s at 72°C (1 kb PCR product/min), followed by a final extension at 72°C for 10 min. To confirm CF overexpression of HA 2bR after recombinant virus infection, a HA2bR-specific forward primer (5Ј-ctccatcttcagccttctgg-3Ј) and a reverse primer from the multiple cloning site of SR(Ϫ) vector (5Ј-tgcaggtcgactctagaggat-3Ј) were used to produce a ϳ1.3-kb fragment (Fig. 1B) . To detect the silencing of rat A 2aR by siRNA, a pair of specific rat A2aR primers (forward: 5Ј-ctcacgcagttccatcttccatctt-3Ј reverse: 5Ј-tccatctgcttcagctgtct-3Ј) was used to amplify rat A 2aR, resulting in a 371 bp fragment (Fig. 2B, top) . To detect silencing of rat A2bR by siRNA, a pair of specific rat A2bR primers (forward: 5Ј-cttctgcacggactttcaca-3, reverse: 5Ј-ggtggcacggtctttactgt-3Ј) was used to amplify rat A 2bR, resulting in a 243 bp fragment (Fig.  2B, bottom) . To demonstrate the presence of adenosine receptor subtypes on CF, we used four pair of specific rat primers for A 1R, A2aR, A2bR, and A3R. A1R (5Ј-tacattggcatcgaggtgct-3Ј, 5Ј-aggtgtggaagtaggtctgt-3Ј), A2aR (5Ј-ctcacgcagagttccatctt-3Ј, 5Јtccatctgct-tcagctgtct-3Ј), A2bR (same as above), and A3R (5Ј-atatggctattcctgggcct-3Ј, 5Јaccagaaacagggacttagc-3Ј) primer pairs yield fragments of 205, 371, 243, and 326 bp respectively.
Western blot analysis. Three days after HA 2bR recombinant virus infection or siRNA transfection, CF lysates were prepared in lysis buffer. Protein samples were separated and transferred onto membranes. Membranes were exposed to 1 g/ml of an anti-A 2aR or anti-A2bR polyclonal antibody (Alpha Diagnostic; San Antonio, TX) and then a secondary horseradish peroxidase-labeled antibody. Protein bands were visualized with the use of ECL plus (Amersham) (Fig. 2B) .
[ (6, 10) . Radioactivity was counted in a liquid scintillation counter. CF proliferation was also assessed through cell counts.
cAMP assays. CF cAMP levels were determined utilizing a direct enzyme immunoassay kit according to manufacturer's (Sigma-Aldrich; St. Louis, MO) instructions. CF were treated for a period of 10 min and cAMP precipitated with 0.1 N HCl. To prevent the breakdown of cAMP, the cells were pretreated with the phosphodiesterase inhibitor rolipram at 10 mol/l for 15 min. To assess the functional In all experiments (n ϭ 3 in triplicate), the transfection efficiency of 70% was consistent. B: mRNA (RT-PCR) and protein (Western blot analysis) levels obtained from CF transfected with A2bR (top) or A2aR (bottom) siRNAs for 72 h. As derived from densitometric scans, bar graphs summarized mRNA and protein expression levels after siRNA transfection (n ϭ 3). As can be observed, rat A2aR siRNA1913 (lane 5) was the most effective siRNA to silence A2aR. mRNA and protein levels were reduced to 13% and 30%, respectively. For rat A2bR siRNA539 (lane 4) was the most effective siRNA to silence A2bR. mRNA and protein levels were reduced to 58% and 35%, respectively. GAPDH and actin were used for normalizing mRNA and protein levels, respectively. coupling of A1R and A3R to Gi, pertussis toxin pretreatment at 100 ng/ml was provided to the cells before agonist treatment.
Statistical analysis. Statistical analysis was performed with Student's t-test or ANOVA. The results were considered statistically significant at P Ͻ 0.05.
RESULTS

ADO receptors in CF.
RT-PCR was used to detect ADO A 1 R, A 2a R, A 2b R, and A 3 R mRNAs in CF. As shown in Fig.  3 , ADO A 1 R, A 2a R, A 2b R, and A 3 R mRNAs were identified in CF. The approximate size of the bands was 205, 371, 243, and 326 base pairs for A 1 R, A 2a R, A 2b R, and A 3 R, respectively.
Proliferation. Results indicate that Cl-Ad or AKI treatment inhibited cell proliferation in a concentration-dependent manner, as assessed through [ 3 H]thymidine incorporation (Fig.  4A) . In all cases, cells continued to proliferate, but the rates of proliferation were reduced with increases in either endogenous or exogenous adenosine levels. To determine the putative ADO receptor subtype-mediated CF proliferation, studies were performed using NECA, CGS-21680, or ATL-193. As one of the most potent A 2b R agonists, NECA inhibited cell proliferation in micromolar concentrations (Fig. 4B) . Treatment of CF with A 2a R-specific agonists CGS-21680 and ATL-193 also resulted in inhibition of cell proliferation (Fig. 4C) . However, compared with 10 Ϫ5 mol/l NECA, which decreased the amount of incorporated [ 3 H]thymidine to 43.2 Ϯ 1.2% of control values, the inhibition of cell proliferation induced by either 10 Ϫ8 mol/l CGS-21680 or ATL-193 was not as pronounced as that induced by NECA (Fig. 4C) . Similar trends were observed on cell counts with the use of CGS-21680 and ATL-193 (Fig. 4F) . NECA induced a decrease in cell number to 71.6 Ϯ 2.6% of control. This decrease was more prominent than those induced by either CGS-21680 or ATL-193 (P Ͻ 0.05).
Protein synthesis. Results indicate that Cl-Ad and AKI significantly and dose dependently inhibited leucine incorporation (Fig. 5A) . NECA also induced a dose-dependent decrease in protein synthesis (Fig. 5B) (Fig. 5C) .
The results of the effects of A 2b R overexpression on CF protein synthesis are summarized in Fig. 6, A Ϫ6 mol/l Cl-Ad (P Ͻ 0.05) or 10 Ϫ4 mol/l NECA (P Ͻ 0.001) (Fig. 7A) . In contrast, silencing of A 2a R did not modify the capacity of 10 Ϫ6 mol/l Cl-Ad (P Ͻ 0.05) or 10 Ϫ4 mol/l NECA to inhibit CF protein synthesis (Fig. 8A) .
Collagen synthesis. As shown in Fig. 5D , Cl-Ad and AKI induced the inhibition of collagen synthesis in a concentrationdependent manner. NECA also induced a concentration-dependent inhibition of collagen synthesis (Fig. 5E ). At 10 Ϫ5 mol/l NECA suppressed collagen synthesis to 71.7 Ϯ 0.8% (P Ͻ 0.05). Similar inhibition of collagen synthesis was observed with the treatment of CF with either CGS-21680 or ATL-193 at 10 Ϫ8 mol/l (Fig. 5F ). CF infected with HA 2b R adenoviruses had a significant decrease in collagen synthesis in the absence of agonist treatment. A significant decrease in CF collagen synthesis was also observed in cells treated with 10 Ϫ6 mol/l Cl-Ad (P Ͻ 0.001) (Fig. 6C) . However, when Cl-Ad or NECA, at 10 Ϫ5 or 10
Ϫ4
mol/l, respectively, was added to HA 2b R overexpressing CF, a significant increase in collagen synthesis was observed (P Ͻ 0.001) (Fig. 6, C and D) . Control virus infection of CF did not affect collagen synthesis compared with uninfected CF in the presence or absence of Cl-Ad or NECA. Silencing of A 2b R led to an increase in CF collagen synthesis in the presence or absence of agonists (Fig. 7B) . In contrast, silencing of A 2a R did not modify the capacity of 10 Ϫ6 mol/l Cl-Ad (P Ͻ 0.05) or 10 Ϫ4 mol/l NECA to inhibit CF collagen synthesis (Fig. 8B) .
cAMP levels. The assessment of cAMP levels in CF was done in untreated cells and cells treated with 10 Ϫ5 mol/l Cl-Ad or 10 Ϫ4 mol/l NECA (Fig. 9) . Results indicate that treatment of uninfected CF significantly increases cAMP levels. CF infected with a reverse-oriented HA 2b R virus showed comparable results to those of uninfected cells. cAMP levels were also determined in sense HA 2b R-overexpressing CF. Results indicate that overexpressing HA 2b R in untreated CF yields enhanced levels of cAMP production (ϳ10-fold vs. control or reverse-oriented control). The treatment of HA 2b R overexpressing CF with Cl-Ad or NECA led to further increases in cAMP levels.
A 1 R and A 3 R are known to mainly couple to G i signaling (17) ADO agonist-induced increases in CF cAMP levels in the presence of pertussis toxin was used as a means to detect functional A 1 R and A 3 R. The results indicate that pertussis toxin pretreatment of CF did not yield greater levels of cAMP, thus indicating that CF do not express functional A 1 R and A 3 R (data not shown).
DISCUSSION
Recent evidence indicates that ADO can act as an inhibitor of CF functions through its interaction with cell surface receptors. However, the role of ADO receptor subtypes, in particular A 2b R, remains unclear. Through the use of molecular approaches (overexpressing or silencing A 2a R and A 2b R) we demonstrate important roles of A 2b R in mediating CF functions. Furthermore, although CF express mRNA levels for all four types of ADO receptors, A 1 R and A 3 R do not appear functionally relevant as ascertained from the failure of these receptors to couple to G i signaling.
The effects of ADO were explored in cultured CF by the exogenous addition of agents such as Cl-Ad or by endogenously enhancing its production through alterations in its metabolism. AKI treatment increases endogenous ADO levels by preventing the rephosphorylation of ADO into AMP (34). Results from the present study demonstrate that both exogenously (Cl-Ad) and endogenously (AKI) enhanced ADO levels can inhibit serum-induced CF proliferation in a dosedependent manner. The magnitude of the decreases for Cl-Ad and AKI are comparable to those reported by Dubey et al. (6, 9, 10) . A pharmacological approach was initially utilized to gain insight into the ADO receptor subtypes that may be involved in modulating CF functions. The ADO analog NECA remains one of the most potent A 2b R agonists known (6, 9, 10, 12, 14, 15) with an EC 50 of ϳ2 ϫ 10 Ϫ6 mol/l. In an attempt to ascertain the involvement of the A 2b R we used NECA in the dose range of 10 Ϫ6 -10 Ϫ4 mol/l. Treatment of CF with NECA decreased proliferation in a concentration-dependent manner. However, NECA can also activate other ADO receptor subtypes in this dose range. Thus the responses elicited by NECA at this dose range are suggestive of the involvement of A 2b R but are not conclusive.
To further establish the relative contributions derived from A 2a R and A 2b R on cell proliferation we utilized agents known to preferentially act as selective A 2a R agonists. CGS-21680 and ATL-193 in the nanomolar dose range in principle do not activate A 2b R but are as potent as NECA in activating A 2a R (1, 14) . The agonist ATL-193 was selected because it has been reported to be 50 times more potent than CGS-21680 for A 2a R binding (31) . Both agents were used at concentrations of 10 Ϫ8 mol/l. Results indicate that CGS-21680 and ATL-193-induced significant inhibitions (70 -80% of control values) in CF thymidine incorporation suggesting a role of A 2a R in CF proliferation. A similar trend was observed in cell count experiments. However, when these results are contrasted to those obtained with 10 Ϫ5 mol/l concentrations of NECA (40% of control values), they suggest that A 2b R may play a prominent role in inhibiting CF proliferation. These results differ from those reported by Dubey et al. (6, 10) that indicate that only micromoles per liter concentrations of CGS-21680 were capable of inhibiting CF proliferation. Altogether, our pharmacological results suggest that both A 2a R and A 2b R may participate in the modulation of CF proliferation.
Experiments performed to evaluate the effects of ADO on total protein synthesis also indicate that both exogenous and endogenous ADO is capable of inhibiting serum-stimulated CF leucine incorporation in a dose-dependent manner. Similar The incorporation of proline was used as a means to assess collagen synthesis. Significant dose-dependent decreases in proline incorporation were observed with Cl-Ad, AKI, and NECA. However, when the A 2a R agonists were used, the magnitude of inhibition achieved was comparable to that generated by 10 Ϫ6 mol/l NECA. These data suggest that A 2 R play important roles in regulating CF collagen synthesis.
As implied by the above discussion of results, the pharmacological characterization of A 2b R-mediated cell functions is far from ideal. Selective A 2b R agonists and antagonists are currently not readily available. A clearer understanding of the role that receptor subtypes may exercise in regulating cell functions can be gained by the use of molecular-based strategies. To elucidate how A 2b R affects CF functions, we generated recombinant adenoviruses to overexpress A 2b R. To control for any possible nonspecific effects of adenoviruses, control (reverse-oriented HA 2b R) viruses were generated. The results indicate that infection of CF with control viruses did not affect leucine or proline synthesis compared with uninfected CF. The overexpression of A 2b R in untreated CF yields significant decreases in basal collagen and protein synthesis. This inhibition likely represents the effects generated by the endogenous ADO because CFs produce significant amounts of ADO (20, 27) . Indeed, the observation of enhanced cAMP levels in untreated, A 2b R-overexpressing cells supports this concept.
These results provide evidence for A 2b R mediation of inhibitory actions on CF protein and collagen synthesis. Cl-Ad treatment at 10 Ϫ6 mol/l decreased protein and collagen synthesis. However, when CF were treated with increasing doses of Cl-Ad or NECA, increases in collagen and protein synthesis were observed. These confounding responses could be due to abnormal receptor coupling (21) or secondary to the excessive production of cAMP (up to ϳ200-fold vs. controls). Alternatively, these responses may indicate that the regulation of protein and collagen synthesis by A 2b R is inherently complex.
siRNA-based technology was chosen to silence rat A 2a R or A 2b R gene expression. We successfully transfected siRNA into CF yielding a substantial degree of A 2b R mRNA and protein downregulation. CF with control siRNA transfection did not alter protein and collagen synthesis compared with CF with transfection reagent alone. The results indicate that the partial abolishment of A 2b R expression yields the enhancement of basal CF protein and collagen synthesis. The enhancement of these CF functions was also present when cells were treated with 10 Ϫ6 mol/l Cl-Ad or 10 Ϫ4 mol/l NECA. The stimulatory effects were not observed in CF transfected with control siRNA. The fact that the partial absence of A 2b R yields the stimulation of basal protein and collagen synthesis suggests that these receptors play key roles in the control of these functions. It also implies that an "imbalance" in ADO receptor subtype expression and activation (likely through endogenous ADO) alters basal cell functions. Altogether, given the absence of effects of A 2a R silencing on ADO-mediated inhibition of CF protein or collagen synthesis, these results support the concept that CF protein and collagen synthesis are critically mediated with A 2b R. It is worth noting that siRNA technology has proven to be minimally cytotoxic and highly specific for reducing the expression of targeted genes compared with antisense-based methodologies (29) .
The signaling mechanisms responsible for A 2b R-mediated inhibition of protein and/or collagen synthesis in CF are not fully known. A 2b R are known to couple to G s proteins and when activated can upregulate cAMP production (10) . Increases in cAMP levels have been associated with the inhibition of cellular functions such as proliferation, DNA, protein and collagen synthesis (7, 8, 10, 11) . Our results indicate that stimulation of CF with adenosine or NECA does indeed elevate cAMP levels within the cells, thus indicating the possibility of cAMP-mediated regulation of protein and/or collagen synthesis. However, as documented in other cell types, A 2b R activation can also increase intracellular levels of calcium (2, 13, 16, 26) that can lead to activation of other signaling pathways. Thus the effects of the A 2b R may be mediated by the simultaneous activation of different signal transduction pathways. There is also the possibility that A 2b R activation may also inhibit protein and/or collagen synthesis through indirect actions such as the suppression of cytokine production (4). Thus much work remains to be done so as to understand how adenosine inhibits CF functions associated with fibrosis.
In conclusion, by utilizing molecular approaches, we provide evidence that A 2b R may be critically involved in the inhibition of CF proliferation, protein, and collagen synthesis. Values were normalized to those derived from untreated control siRNA-transfected cells. Fig. 9 . Determination of cAMP levels in either uninfected CF, reverse (R)-oriented HA2bR-infected CF, or HA2bR-infected CF sense (S) groups. Cells were either untreated or treated with Cl-Ad or NECA. Data are means Ϯ SD. Significant differences vs. control were observed with agonist treatment within each group. Increases in cAMP levels in HA2bR-infected (S) CF were significantly different vs. corresponding controls or treated in either uninfected or R-infected cells.
The development of A 2b R knockout animals should further clarify the role of A 2b R in the modulation of these functions.
